The following main treatment approaches are currently used in locally advanced adenocarcinomas of the oesophagus and gastrooesophageal junction (GOJ): preoperative chemoradiotherapy and surgery, and perioperative chemotherapy and surgery. While preoperative chemoradiotherapy is used primarily in oesophageal tumours, perioperative chemotherapy is the treatment of choice in Western countries for gastric cancer. The optimal treatment strategy for GOJ adenocarcinoma is still not clear. In comparison to other malignancies, biomarkers are used as predictive factors in distal oesophageal and GOJ adenocarcinomas in a very limited way, and moreover, only in metastatic stages (e.g., HER2 status, or microsatellite instability status). The aim of the article is to provide an overview of current treatment options in locally advanced adenocarcinomas of oesophagus and GOJ based on the latest evidence, including the possible potential of predictive biomarkers in optimizing treatment.

Department of Field Surgery Faculty of Military Health Sciences University of Defence 500 05 Hradec Králové Czech Republic

Department of Oncology and Radiotherapy Charles University Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové 500 05 Hradec Králové Czech Republic

Department of Surgery Charles University Faculty of Medicine in Hradec Králové and University Hospital Hradec Králové 500 05 Hradec Králové Czech Republic

Zobrazit více v PubMed

Xie Y., Shi L., He X., Luo Y. Gastrointestinal cancers in China, the USA, and Europe. Gastroenterol. Rep. 2021;9:1–104. doi: 10.1093/gastro/goab010. PubMed DOI PMC

Pohl H., Welch H.G. The role of overdiagnosis and reclassification in the marked increase of esophageal adenocarcinoma incidence. J. Natl. Cancer Inst. 2005;97:142–146. doi: 10.1093/jnci/dji024. PubMed DOI

Kort E.J., Sevensma E., Fitzgerald T.L. Trends in esophageal cancer and body mass index by race and gender in the state of Michigan. BMC Gastroenterol. 2009;9:47. doi: 10.1186/1471-230X-9-47. PubMed DOI PMC

Marabotto E., Pellegatta G., Sheijani A.D., Ziola S., Zentilin P., De Marzo M.G., Giannini E.G., Ghisa M., Barberio B., Scarpa M., et al. Prevention Strategies for Esophageal Cancer-An Expert Review. Cancers. 2021;13:2183. doi: 10.3390/cancers13092183. PubMed DOI PMC

Uhlenhopp D.J., Then E.O., Sunkara T., Gaduputi V. Epidemiology of esophageal cancer: Update in global trends, etiology and risk factors. Clin. J. Gastroenterol. 2020;13:1010–1021. doi: 10.1007/s12328-020-01237-x. PubMed DOI

Siewert J.R., Hölscher A.H., Becker K., Gössner W. Cardia cancer: Attempt at a therapeutically relevant classification. Der Chir. Z. Geb. Oper. Medizen. 1987;58:25–32. PubMed

Siewert J.R., Stein H.J. Carcinoma of the cardia: Carcinoma of the gastroesophageal junction-classification, pathology and extent of resection. Dis. Esophagus. 1996;9:173–182.

International Union against Cancer (UICC) In: In TNM Classification of Malignant Tumours. 6th ed. Sobin L.H., Wittekind C., editors. Wiley-Blackwell; New York, NY, USA: 2009.

International Union against Cancer (UICC) In: In TNM Classification of Malignant Tumours. 7th ed. Sobin L.H., Gospodarowicz M.K., Wittekind C., editors. Wiley-Blackwell; New York, NY, USA: 2009. pp. 67–77.

International Union against Cancer (UICC) In: In TNM Classification of Malignant Tumours. 8th ed. Brierley J.D., Gospodarowicz M.K., Wittekind C., editors. Wiley-Blackwell; New York, NY, USA: 2017. pp. 57–67.

Kurokawa Y., Takeuchi H., Doki Y., Mine S., Terashima M., Yasuda T., Yoshida K., Daiko H., Sakuramoto S., Yoshikawa T., et al. Mapping of Lymph Node Metastasis From Esophagogastric Junction Tumors: A Prospective Nationwide Multicenter Study. Ann. Surg. 2021;274:120–127. doi: 10.1097/SLA.0000000000003499. PubMed DOI

Lordick F., Mariette C., Haustermans K., Obermannová R., Arnold D., ESMO Guidelines Committee Oesophageal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann. Oncol. 2016;27:v50–v57. doi: 10.1093/annonc/mdw329. PubMed DOI

Shah M.A., Kennedy E.B., Catenacci D.V., Deighton D.C., Goodman K.A., Malhotra N.K., Willett C., Stiles B., Sharma P., Tang L., et al. Treatment of Locally Advanced Esophageal Carcinoma: ASCO Guideline. J. Clin. Oncol. 2020;38:2677–2694. doi: 10.1200/JCO.20.00866. PubMed DOI

NCCN Clinical Practice Guidelines in Oncology, NCCN Guidelines Version 2. 2020. [(accessed on 9 June 2020)]. Esophageal and Esophagogastric Junction Cancer. Available online: https://www.nccn.org/professionals/physician_gls/pdf/esophageal.pdf.

Kelly R.J., Ajani J.A., Kuzdzal J., Zander T., Van Cutsem E., Piessen G., Mendez G., Feliciano J., Motoyama S., Lièvre A., et al. Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer. N. Engl. J. Med. 2021;384:1191–1203. doi: 10.1056/NEJMoa2032125. PubMed DOI

Cooper J.S., Guo M.D., Herskovic A., Macdonald J.S., Martenson J.A., Jr., Al-Sarraf M., Byhardt R., Russell A.H., Beitler J.J., Spencer S., et al. Chemoradiotherapy of locally advanced esophageal cancer: Long-term follow-up of a prospective randomized trial (RTOG 85–01) Radiat. Ther. Oncol. Group. JAMA. 1999;281:1623–1627. doi: 10.1001/jama.281.17.1623. PubMed DOI

Minsky B.D., Pajak T.F., Ginsberg R.J., Pisansky T.M., Martenson J., Komaki R., Okawara G., Rosenthal S.A., Kelsen D.P. INT 0123 (Radiation Therapy Oncology Group 94-05) phase III trial of combined-modality therapy for esophageal cancer: High-dose versus standard-dose radiation therapy. J. Clin. Oncol. 2002;20:1167–1174. doi: 10.1200/JCO.2002.20.5.1167. PubMed DOI

Urschel J.D., Vasan H. A meta-analysis of randomized controlled trials that compared neoadjuvant chemoradiation and surgery to surgery alone for resectable esophageal cancer. Am. J. Surg. 2003;185:538–543. doi: 10.1016/S0002-9610(03)00066-7. PubMed DOI

Fiorica F., Di Bona D., Schepis F., Licata A., Shahied L., Venturi A., Falchi A.M., Craxì A., Cammà C. Preoperative chemoradiotherapy for oesophageal cancer: A systematic review and meta-analysis. Gut. 2004;53:925–930. doi: 10.1136/gut.2003.025080. PubMed DOI PMC

Gebski V., Burmeister B., Smithers B.M., Foo K., Zalcberg J., Simes J. Survival benefits from neoadjuvant chemoradiotherapy or chemotherapy in oesophageal carcinoma: A metaanalysis. Lancet Oncol. 2007;8:226–234. doi: 10.1016/S1470-2045(07)70039-6. PubMed DOI

Walsh T.N., Noonan N., Hollywood D., Kelly A., Keeling N., Hennessy T.P. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N. Engl. J. Med. 1996;335:462–467. doi: 10.1056/NEJM199608153350702. PubMed DOI

Walsh T.N., Grennell M., Mansoor S., Kelly A. Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Dis. Esophagus. 2002;15:121–124. doi: 10.1046/j.1442-2050.2002.00214.x. PubMed DOI

Urba S.G., Orringer M.B., Turrisi A., Iannettoni M., Forastiere A., Strawderman M. Randomized trial of preoperative chemoradiation versus surgery alone in patients with locoregional esophageal carcinoma. J. Clin. Oncol. 2001;19:305–313. doi: 10.1200/JCO.2001.19.2.305. PubMed DOI

Burmeister B.H., Smithers B.M., Gebski V., Fitzgerald L., Simes R.J., Devitt P., Ackland S., Gotley D.C., Joseph D., Millar J., et al. Trans-Tasman Radiation Oncology Group; Australasian Gastro-Intestinal Trials Group. Surgery alone versus chemoradiotherapy followed by surgery for resectable cancer of the oesophagus: A randomised controlled phase III trial. Lancet Oncol. 2005;6:659–668. doi: 10.1016/S1470-2045(05)70288-6. PubMed DOI

Tepper J., Krasna M.J., Niedzwiecki D., Hollis D., Reed C.E., Goldberg R., Kiel K., Willett C., Sugarbaker D., Mayer R. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J. Clin. Oncol. 2008;26:1086–1092. doi: 10.1200/JCO.2007.12.9593. PubMed DOI PMC

van Hagen P., Hulshof M.C., van Lanschot J.J., Steyerberg E.W., van Berge Henegouwen M.I., Wijnhoven B.P., Richel D.J., Nieuwenhuijzen G.A.P., Hospers G.A.P., Bonenkamp J.J., et al. Preoperative chemoradiotherapy for esophageal or junctional cancer. N. Engl. J. Med. 2012;366:2074–2084. doi: 10.1056/NEJMoa1112088. PubMed DOI

Shapiro J., van Lanschot J.J., Hulshof M.C., van Hagen P., van Berge Henegouwen M.I., Wijnhoven B.P., van Laarhoven H.W., Nieuwenhuijzen G.A.P., Hospers G.A.P., Bonenkamp J.J., et al. Neoadjuvant chemoradiotherapy plus surgery versus surgery alone for oesophageal or junctional cancer (CROSS): Long-term results of a randomised controlled trial. Lancet Oncol. 2015;16:1090–1098. doi: 10.1016/S1470-2045(15)00040-6. PubMed DOI

Eyck B.M., van Lanschot J.J.B., Hulshof M.C.C.M., van der Wilk B.J., Shapiro J., van Hagen P., van Berge Henegouwen M.I., Wijnhoven B.P.L., van Laarhoven H.W.M., Nieuwenhuijzen G.A.P., et al. Ten-Year Outcome of Neoadjuvant Chemoradiotherapy Plus Surgery for Esophageal Cancer: The Randomized Controlled CROSS Trial. J. Clin. Oncol. 2021;39:1995–2004. doi: 10.1200/JCO.20.03614. PubMed DOI

Macdonald J.S., Smalley S.R., Benedetti J., Hundahl S.A., Estes N.C., Stemmermann G.N., Haller D.G., Ajani J.A., Gunderson L.L., Jessup J.M., et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N. Engl. J. Med. 2001;345:725–730. doi: 10.1056/NEJMoa010187. PubMed DOI

Smalley S.R., Benedetti J.K., Haller D.G., Hundahl S.A., Estes N.C., Ajani J.A., Gunderson L.L., Goldman B., Martenson J.A., Milburn Jessup J., et al. Updated analysis of SWOG-directed intergroup study 0116: A phase III trial of adjuvant radiochemotherapy versus observation after curative gastric cancer resection. J. Clin. Oncol. 2012;30:2327–2333. doi: 10.1200/JCO.2011.36.7136. PubMed DOI PMC

Fuchs C.S., Niedzwiecki D., Mamon H.J., Tepper J.E., Ye X., Swanson R.S., Enzinger P.C., Haller D.G., Dragovich T., Alberts S.R., et al. Adjuvant Chemoradiotherapy with Epirubicin, Cisplatin, and Fluorouracil Compared with Adjuvant Chemoradiotherapy with Fluorouracil and Leucovorin After Curative Resection of Gastric Cancer: Results From CALGB 80101 (Alliance) J. Clin. Oncol. 2017;35:3671–3677. doi: 10.1200/JCO.2017.74.2130. PubMed DOI PMC

Ychou M., Boige V., Pignon J.P., Conroy T., Bouché O., Lebreton G., Ducourtieux M., Bedenne L., Fabre J.-M., Saint-Aubert B., et al. Perioperative chemotherapy compared with surgery alone for resectable gastroesophageal adenocarcinoma: An FNCLCC and FFCD multicenter phase III trial. J. Clin. Oncol. 2011;29:1715–1721. doi: 10.1200/JCO.2010.33.0597. PubMed DOI

Cunningham D., Allum W.H., Stenning S.P., Thompson J.N., Van de Velde C.J., Nicolson M., Scarffe J.H., Lofts F.J., Falk S.J., Iveson T.J., et al. MAGIC Trial Participants. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N. Engl. J. Med. 2006;355:11–20. doi: 10.1056/NEJMoa055531. PubMed DOI

Al-Batran S.E., Homann N., Pauligk C., Goetze T.O., Meiler J., Kasper S., Kopp H.-G., Mayer F., Haag G.M., Luley K., et al. FLOT4-AIO Investigators. Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): A randomised, phase 2/3 trial. Lancet. 2019;393:1948–1957. doi: 10.1016/S0140-6736(18)32557-1. PubMed DOI

Allum W.H., Stenning S.P., Bancewicz J., Clark P.I., Langley R.E. Long-term results of a randomized trial of surgery with or without preoperative chemotherapy in esophageal cancer. J. Clin. Oncol. 2009;27:5062–5067. doi: 10.1200/JCO.2009.22.2083. PubMed DOI

Kelsen D.P., Ginsberg R., Pajak T.F., Sheahan D.G., Gunderson L., Mortimer J., Estes N., Haller D.G., Ajani J., Kocha W., et al. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N. Engl. J. Med. 1998;339:1979–1984. doi: 10.1056/NEJM199812313392704. PubMed DOI

Alderson D., Cunningham D., Nankivell M., Blazeby J.M., Griffin S.M., Crellin A., Grabsch H.I., Langer R., Pritchard S., Okines A., et al. Neoadjuvant cisplatin and fluorouracil versus epirubicin, cisplatin, and capecitabine followed by resection in patients with oesophageal adenocarcinoma (UK MRC OE05): An open-label, randomised phase 3 trial. Lancet Oncol. 2017;18:1249–1260. doi: 10.1016/S1470-2045(17)30447-3. PubMed DOI PMC

Sasako M., Sakuramoto S., Katai H., Kinoshita T., Furukawa H., Yamaguchi T., Nashimoto A., Fujii M., Nakajima T., Ohashi Y. Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J. Clin. Oncol. 2011;29:4387–4393. doi: 10.1200/JCO.2011.36.5908. PubMed DOI

Noh S.H., Park S.R., Yang H.K., Chung H.C., Chung I.J., Kim S.W., Kim H.H., Choi J.H., Kim H.K., Yu W., et al. CLASSIC trial investigators. Adjuvant capecitabine plus oxaliplatin for gastric cancer after D2 gastrectomy (CLASSIC): 5-year follow-up of an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15:1389–1396. doi: 10.1016/S1470-2045(14)70473-5. PubMed DOI

Cats A., Jansen E.P.M., van Grieken N.C.T., Sikorska K., Lind P., Nordsmark M., Kranenbarg E.M.K., Boot H., Trip A.K., Maurits Swellengrebel H.A., et al. CRITICS investigators; CRITICS investigators. Chemotherapy versus chemoradiotherapy after surgery and preoperative chemotherapy for resectable gastric cancer (CRITICS): An international, open-label, randomised phase 3 trial. Lancet Oncol. 2018;19:616–628. doi: 10.1016/S1470-2045(18)30132-3. PubMed DOI

Stahl M., Walz M.K., Stuschke M., Lehmann N., Meyer H.J., Riera-Knorrenschild J., Langer P., Engenhart-Cabillic R., Bitzer M., Königsrainer A., et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J. Clin. Oncol. 2009;27:851–856. doi: 10.1200/JCO.2008.17.0506. PubMed DOI

Stahl M., Walz M.K., Riera-Knorrenschild J., Stuschke M., Sandermann A., Bitzer M., Wilke H., Wilfried Budach W. Preoperative chemotherapy versus chemoradiotherapy in locally advanced adenocarcinomas of the oesophagogastric junction (POET): Long-term results of a controlled randomised trial. Eur. J. Cancer. 2017;81:183–190. doi: 10.1016/j.ejca.2017.04.027. PubMed DOI

Reynolds J.V., Preston S.R., O’Neill B., Lowery M.A., Baeksgaard L., Crosby T., Cunningham M., Cuffe S., Griffiths G.O., Roy R., et al. Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol) J. Clin. Oncol. 2021;39((Suppl. 15)):4004. doi: 10.1200/JCO.2021.39.15_suppl.4004. DOI

Hoeppner J., Lordick F., Brunner T., Glatz T., Bronsert P., Röthling N., Schmoor C., Lorenz D., Ell C., Hopt U.T., et al. ESOPEC: Prospective randomized controlled multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (NCT02509286) BMC Cancer. 2016;16:503. doi: 10.1186/s12885-016-2564-y. PubMed DOI PMC

Leong T., Smithers B.M., Michael M., Gebski V., Boussioutas A., Miller D., Simes J., Zalcberg J., Haustermans K., Lordick F., et al. TOPGEAR: A randomised phase III trial of perioperative ECF chemotherapy versus preoperative chemoradiation plus perioperative ECF chemotherapy for resectable gastric cancer (an international, intergroup trial of the AGITG/TROG/EORTC/NCIC CTG) BMC Cancer. 2015;15:532. doi: 10.1186/s12885-015-1529-x. PubMed DOI PMC

Leong T., Smithers B.M., Haustermans K., Michael M., Gebski V., Miller D., Zalcberg J., Boussioutas A., Findlay M., O’Connell R.L., et al. TOPGEAR: A Randomized, Phase III Trial of Perioperative ECF Chemotherapy with or Without Preoperative Chemoradiation for Resectable Gastric Cancer: Interim Results from an International, Intergroup Trial of the AGITG, TROG, EORTC and CCTG. Ann. Surg. Oncol. 2017;24:2252–2258. doi: 10.1245/s10434-017-5830-6. PubMed DOI

Cunningham D., Stenning S.P., Smyth E.C., Okines A.F., Allum W.H., Rowley S., Stevenson L., Grabsch H.I., Alderson D., Crosby T., et al. Peri-operative chemotherapy with or without bevacizumab in operable oesophagogastric adenocarcinoma (UK Medical Research Council ST03): Primary analysis results of a multicentre, open-label, randomised phase 2–3 trial. Lancet Oncol. 2017;18:357–370. doi: 10.1016/S1470-2045(17)30043-8. PubMed DOI PMC

Bang Y.J., Van Cutsem E., Feyereislova A., Chung H.C., Shen L., Sawaki A., Lordick F., Ohtsu A., Omuro Y., Satoh T., et al. ToGA Trial Investigators. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomised controlled trial. Lancet. 2010;376:687–697. doi: 10.1016/S0140-6736(10)61121-X. PubMed DOI

Safran H., Winter K.A., Wigle D.A., DiPetrillo T.A., Haddock M.G., Hong T.S., Leichman L.P., Rajdev L., Resnick M.B., Kachnic L.A., et al. Trastuzumab with trimodality treatment for esophageal adenocarcinoma with HER2 overexpression: NRG Oncology/RTOG 1010. J. Clin. Oncol. 2020;38:4500. doi: 10.1200/JCO.2020.38.15_suppl.4500. PubMed DOI PMC

Hofheinz R.D., Haag G.M., Ettrich T.J., Borchert K., Kretzschmar A., Teschendorf C., Siegler G.M., Ebert M.P., Goekkurt E., Welslau M., et al. Perioperative trastuzumab and pertuzumab in combination with FLOT versus FLOT alone for HER2-positive resectable esophagogastric adenocarcinoma: Final results of the PETRARCA multicenter randomized phase II trial of the AIO. J. Clin. Oncol. 2020;38((Suppl. 15)):4502. doi: 10.1200/JCO.2020.38.15_suppl.4502. DOI

Tabernero J., Hoff P.M., Shen L., Ohtsu A., Shah M.A., Cheng K., Song C., Wu H., Eng-Wong J., Kim K., et al. Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): Final analysis of a double-blind, randomised, placebo-controlled phase 3 study. Lancet Oncol. 2018;19:1372–1384. doi: 10.1016/S1470-2045(18)30481-9. PubMed DOI

Wagner A.D., Grabsch H.I., Mauer M., Marreaud S., Caballero C., Thuss-Patience P., Mueller L., Elme A., Moehler M.H., Martens U., et al. EORTC-1203-GITCG-the “INNOVATION”-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: A randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group. BMC Cancer. 2019;19:494. doi: 10.1186/s12885-019-5675-4. PubMed DOI PMC

Homann N., Lorenzen S., Schenk M., Thuss-Patience P.C., Goekkurt E., Hofheinz R.D., Kretzschmar A., Bolling C., Angermeier S., Wicki A., et al. Interim safety analysis of the DANTE trial: Perioperative atezolizumab in combination with FLOT versus FLOT alone in patients with resectable esophagogastric adenocarcinoma—A randomized, open-label phase II trial of the German Gastric Group at the AIO and SAKK. J. Clin. Oncol. 2020;38((Suppl. 15)):4549.

Bang Y.J., Van Cutsem E., Fuchs C.S., Ohtsu A., Tabernero J., Ilson D.H., Hyung W.J., Strong V.E., Goetze T.O., Yoshikawa T., et al. KEYNOTE-585: Phase III study of perioperative chemotherapy with or without pembrolizumab for gastric cancer. Future Oncol. 2019;15:943–952. doi: 10.2217/fon-2018-0581. PubMed DOI

Smyth E., Knödler M., Giraut A., Mauer M., Nilsson M., Van Grieken N., Wagner A.D., Moehler M., Lordick F. VESTIGE: Adjuvant Immunotherapy in Patients With Resected Esophageal, Gastroesophageal Junction and Gastric Cancer Following Preoperative Chemotherapy With High Risk for Recurrence (N+ and/or R1): An Open Label Randomized Controlled Phase-2-Study. Front. Oncol. 2020;9:1320. doi: 10.3389/fonc.2019.01320. PubMed DOI PMC

Paver E.C., Cooper W.A., Colebatch A.J., Ferguson P.M., Hill S.K., Lum T., Shin J.S., O’Toole S., Anderson L., Scolyer R.A., et al. Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: A guide to immunohistochemistry implementation and interpretation. Pathology. 2021;53:141–156. doi: 10.1016/j.pathol.2020.10.007. PubMed DOI

Park R., Da Silva L.L., Saeed A. Immunotherapy Predictive Molecular Markers in Advanced Gastroesophageal Cancer: MSI and Beyond. Cancers. 2021;13:1715. doi: 10.3390/cancers13071715. PubMed DOI PMC

Högner A., Thuss-Patience P. Immune Checkpoint Inhibition in Oesophago-Gastric Carcinoma. Pharmaceuticals. 2021;14:151. doi: 10.3390/ph14020151. PubMed DOI PMC

Marabelle A., Le D.T., Ascierto P.A., Di Giacomo A.M., De Jesus-Acosta A., Delord J.P., Geva R., Gottfried M., Penel N., Hansen A.R., et al. Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. J. Clin. Oncol. 2020;38:1–10. doi: 10.1200/JCO.19.02105. PubMed DOI PMC

Marabelle A., Fakih M., Lopez J., Shah M., Shapira-Frommer R., Nakagawa K., Chung H.C., Kindler H.L., Lopez-Martin J.A., Miller W.H., Jr., et al. Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: Prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study. Lancet Oncol. 2020;21:1353–1365. doi: 10.1016/S1470-2045(20)30445-9. PubMed DOI

Fuchs C.S., Doi T., Jang R.W., Muro K., Satoh T., Machado M., Sun W., Jalal S.I., Shah M.A., Metges J.P., et al. Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: Phase 2 clinical KEYNOTE-059 Trial. JAMA Oncol. 2018;4:e180013. doi: 10.1001/jamaoncol.2018.0013. PubMed DOI PMC

Marrelli D., Polom K., Pascale V., Vindigni C., Piagnerelli R., De Franco L., Ferrara F., Roviello G., Garosi L., Petrioli R., et al. Strong prognostic value of microsatellite instability in intestinal type non-cardia gastric cancer. Ann. Surg. Oncol. 2016;23:943–950. doi: 10.1245/s10434-015-4931-3. PubMed DOI

Haag G.M., Czink E., Ahadova A., Schmidt T., Sisic L., Blank S., Heger U., Apostolidis L., Berger A.K., Springfeld C., et al. Prognostic significance of microsatellite-instability in gastric and gastroesophageal junction cancer patients undergoing neoadjuvant chemotherapy. Int. J. Cancer. 2019;144:1697–1703. doi: 10.1002/ijc.32030. PubMed DOI

Hashimoto T., Kurokawa Y., Takahashi T., Miyazaki Y., Tanaka K., Makino T., Yamasaki M., Nakajima K., Ikeda J.I., Mori M., et al. Predictive value of MLH1 and PD-L1 expression for prognosis and response to preoperative chemotherapy in gastric cancer. Gastric Cancer. 2019;22:785–792. doi: 10.1007/s10120-018-00918-4. PubMed DOI

Kim S.Y., Choi Y.Y., An J.Y., Shin H.B., Jo A., Choi H., Seo S.H., Bang H.J., Cheong J.H., Hyung W.J., et al. The benefit of microsatellite instability is attenuated by chemotherapy in stage II and stage III gastric cancer: Results from a large cohort with subgroup analyses. Int. J. Cancer. 2015;137:819–825. doi: 10.1002/ijc.29449. PubMed DOI

Beghelli S., de Manzoni G., Barbi S., Tomezzoli A., Roviello F., Di Gregorio C., Vindigni C., Bortesi L., Parisi A., Saragoni L., et al. Microsatellite instability in gastric cancer is associated with better prognosis in only stage II cancers. Surgery. 2006;139:347–356. doi: 10.1016/j.surg.2005.08.021. PubMed DOI

Shitara K., Özgüroğlu M., Bang Y.J., Di Bartolomeo M., Mandalà M., Ryu M.H., Fornaro L., Olesiński T., Caglevic C., Chung H.C., et al. Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE061): A randomised, open-label, controlled, phase 3 trial. Lancet. 2018;392:123–133. doi: 10.1016/S0140-6736(18)31257-1. PubMed DOI

Oki E., Kakeji Y., Zhao Y., Yoshida R., Ando K., Masuda T., Ohgaki K., Morita M., Yoshihiko Maehara Y. Chemosensitivity and survival in gastric cancer patients with microsatellite instability. Ann. Surg. Oncol. 2009;16:2510–2515. doi: 10.1245/s10434-009-0580-8. PubMed DOI

Miceli R., An J., Di Bartolomeo M., Morano F., Kim S.T., Park S.H., Choi M.G., Lee J.H., Raimondi A., Fucà G., et al. Prognostic impact of microsatellite instability in Asian gastric cancer patients enrolled in the ARTIST trial. Oncology. 2019;97:38–43. doi: 10.1159/000499628. PubMed DOI

Dos Santos N.R., Seruca R., Constância M., Seixas M., Sobrinho-Simões M. Microsatellite instability at multiple loci in gastric carcinoma: Clinicopathologic implications and prognosis. Gastroenterology. 1996;110:38–44. doi: 10.1053/gast.1996.v110.pm8536886. PubMed DOI

Fang W.L., Chang S.C., Lan Y.T., Huang K.H., Chen J.H., Lo S.S., Hsieh M.C., Li A.F.Y., Wu C.W., Chiou S.H. Microsatellite instability is associated with a better prognosis for gastric cancer patients after curative surgery. World J. Surg. 2012;36:2131–2138. doi: 10.1007/s00268-012-1652-7. PubMed DOI

Zhu L., Li Z., Wang Y., Zhang C., Liu Y., Qu X. Microsatellite instability and survival in gastric cancer: A systematic review and meta-analysis. Mol. Clin. Oncol. 2015;3:699–705. doi: 10.3892/mco.2015.506. PubMed DOI PMC

Choi Y.Y., Bae J.M., An J.Y., Kwon I.G., Cho I., Shin H.B., Eiji T., Aburahmah M., Kim H.I., Cheong J.H., et al. Is microsatellite instability a prognostic marker in gastric cancer? A systematic review with meta-analysis. J. Surg. Oncol. 2014;110:129–135. doi: 10.1002/jso.23618. PubMed DOI

Smyth E.C., Wotherspoon A., Peckitt C., Gonzalez D., Hulkki-Wilson S., Eltahir Z., Fassan M., Rugge M., Valeri N., Okines A., et al. Mismatch repair deficiency, microsatellite instability, and survival: An exploratory analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017;3:1197–1203. doi: 10.1001/jamaoncol.2016.6762. PubMed DOI PMC

Choi Y.Y., Kim H., Shin S.-J., Kim H.Y., Lee J., Yang H.K., Kim W.H., Kim Y.W., Kook M.C., Park Y.K., et al. Microsatellite instability and programmed cell death-ligand 1 expression in stage II/III gastric cancer: Post hoc analysis of the CLASSIC randomized controlled study. Ann. Surg. 2019;270:309–316. doi: 10.1097/SLA.0000000000002803. PubMed DOI

Pietrantonio F., Miceli R., Raimondi A., Kim Y.W., Kang W.K., Langley R.E., Choi Y.Y., Kim K.M., Nankivell M.G., Morano F., et al. Individual patient data meta-analysis of the value of microsatellite instability as a biomarker in gastric cancer. J. Clin. Oncol. 2019;37:3392–3400. doi: 10.1200/JCO.19.01124. PubMed DOI

Smyth E.C. Chemotherapy for resectable microsatellite instability-high gastric cancer? Lancet Oncol. 2020;21:204. doi: 10.1016/S1470-2045(20)30025-5. PubMed DOI

Shibata D., Weiss L.M. Epstein-Barr virus-associated gastric adenocarcinoma. Am. J. Pathol. 1992;140:769–774. PubMed PMC

Dai C., Geng R., Wang C., Wong A., Qing M., Hu J., Sun Y., Lo A.W.I., Li J. Concordance of immune checkpoints within tumor immune contexture and their prognostic significance in gastric cancer. Mol. Oncol. 2016;10:1551–1558. doi: 10.1016/j.molonc.2016.09.004. PubMed DOI PMC

Kim S.T., Cristescu R., Bass A.J., Kim K.M., Odegaard J.I., Kim K., Liu X.Q., Sher X., Jung H., Lee M., et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat. Med. 2018;24:1449–1458. doi: 10.1038/s41591-018-0101-z. PubMed DOI

Stanland L.J., Luftig M.A. The Role of EBV-Induced Hypermethylation in Gastric Cancer Tumorigenesis. Viruses. 2020;12:1222. doi: 10.3390/v12111222. PubMed DOI PMC

Choi S.J., Shin Y.S., Kang B.W., Kim J.G., Won K.J., Lieberman P.M., Cho H., Kang H. DNA hypermethylation induced by Epstein-Barr virus in the development of Epstein-Barr virus-associated gastric carcinoma. Arch. Pharm. Res. 2017;40:894–905. doi: 10.1007/s12272-017-0939-5. PubMed DOI

Setia N., Wang C.X., Lager A., Maron S., Shroff S., Arndt N., Peterson B., Kupfer S.S., Ma C., Misdraji J., et al. Morphologic and molecular analysis of early-onset gastric cancer. Cancer. 2020;127:103–114. doi: 10.1002/cncr.33213. PubMed DOI

Koh J., Nam S.K., Roh H., Kim J., Lee B.C., Kim J.W., Ahn S.H., Park D.J., Kim H.H., Park K.U., et al. Somatic mutational profiles of stage II and III gastric cancer according to tumor microenvironment immune type. Genes Chromosomes Cancer. 2019;58:12–22. doi: 10.1002/gcc.22683. PubMed DOI

Grosser B., Kohlruss M., Slotta-Huspenina J., Jesinghaus M., Pfarr N., Steiger K., Novotny A., Gaida M.M., Schmidt T., Hapfelmeier A., et al. Impact of Tumor Localization and Molecular Subtypes on the Prognostic and Predictive Significance of p53 Expression in Gastric Cancer. Cancers. 2020;12:1689. doi: 10.3390/cancers12061689. PubMed DOI PMC

Vošmik M., Vošmiková H., Sieglová K., Sirák I., Laco J., Ryška A., Petera J., Melichar B., Soumarová R. HPV Status and Mutation Analysis Using Multiparallel Sequencing in Distal Oesophageal and Gastro-oesophageal Junction Adenocarcinomas. Folia Biol. 2018;64:41–45. PubMed

Schulz-Heddergott R., Moll U.M. Gain-of-Function (GOF) Mutant p53 as Actionable Therapeutic Target. Cancers. 2018;10:188. doi: 10.3390/cancers10060188. PubMed DOI PMC

Zhu G., Pan C., Bei J.X., Li B., Liang C., Xu Y., Fu X. Mutant p53 in Cancer Progression and Targeted Therapies. Front. Oncol. 2020;10:595187. doi: 10.3389/fonc.2020.595187. PubMed DOI PMC

Graziano F., Humar B., Guilford P. The role of the E-cadherin gene (CDH1) in diffuse gastric cancer susceptibility: From the laboratory to clinical practice. Ann Oncol. 2003;14:1705–1713. doi: 10.1093/annonc/mdg486. PubMed DOI

Zhao H., Hu H., Chen B., Xu W., Zhao J., Huang C., Xing Y., Lv H., Nie C., Wang J., et al. Overview on the Role of E-Cadherin in Gastric Cancer: Dysregulation and Clinical Implications. Front. Mol. Biosci. 2021;8:689139. doi: 10.3389/fmolb.2021.689139. PubMed DOI PMC

Doebele R.C., Drilon A., Paz-Ares L., Siena S., Shaw A.T., Farago A.F., Blakely C.M., Seto T., Cho B.C., Tosi D., et al. trial investigators. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: Integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21:271–282. doi: 10.1016/S1470-2045(19)30691-6. PubMed DOI PMC

Hong D.S., DuBois S.G., Kummar S., Farago A.F., Albert C.M., Rohrberg K.S., van Tilburg C.M., Nagasubramanian R., Berlin J.D., Federman N., et al. Larotrectinib in patients with TRK fusion-positive solid tumours: A pooled analysis of three phase 1/2 clinical trials. Lancet Oncol. 2020;21:531–540. doi: 10.1016/S1470-2045(19)30856-3. PubMed DOI PMC

Cancer Genome Atlas Research Network Comprehensive molecular characterization of gastric adenocarcinoma. Nature. 2014;513:202–209. doi: 10.1038/nature13480. PubMed DOI PMC

Cancer Genome Atlas Research Network Integrated genomic characterization of oesophageal carcinoma. Nature. 2017;541:169–175. doi: 10.1038/nature20805. PubMed DOI PMC